Leishmaniasis<unk>  is primarily used for the treatment of visceral and New World cutaneous leishmaniasis, and is undergoing clinical trials for this use in several countries. This drug is now listed as a core medication for the treatment of leishmaniasis under the WHO Model List of Essential Medicines. Several medical agents have some efficacy against visceral or cutaneous leishmaniasis, however, a 2005 survey concluded that<unk>  is the only effective oral treatment for both forms of leishmaniasis. Amoeba infections<unk>  has been used successfully in some cases of the very rare, but highly lethal, brain infection by the amoeba, Naegleria fowleri, acquired through water entering the nose during a plunge in contaminated water. It has orphan drug status in the United States for acanthamoeba keratitis and primary amebic meningoencephalitis (PAM). Pregnancy and breastfeeding<unk>  is listed as pregnancy category D by the FDA. This means there is evidence-based adverse reaction data from investigational or marketing experience or studies in humans of harm to the human fetus. Despite this evidence, the potential benefits of<unk>  may warrant use of the drug in pregnant women despite potential risks. A pregnancy test should be done prior to starting treatment. Effective birth control should be used while on<unk>  and 5 months after discontinuation of treatment. Its use during breast feeding is most likely unsafe.
Miltefosine
Nortilidine
Colestilan
Milrinone
Ibutilide
Dofetilide
Adenosine
Maprotiline